Hereditary cancer testing, including the MyRisk® Hereditary Cancer Test, is one of many steps taken by patients and their family members to better understand and minimize their personal cancer risk, identify at-risk family members, and explore medical management options that may improve survival and quality of life. While genetic test results can provide valuable information regarding cancer risks and clinical management, there is still much to be learned.
Currently, there are many hereditary cancer and tumor-specific research studies being planned or already underway. While Myriad may not be a sponsor of these studies or other resources, we want to bring the opportunity to participate in them to your attention. The table below provides examples of a few of these studies and resources.
Based on your genetic test result, you may qualify to participate in one or more research studies or receive access to additional patient support resources. Participation in research studies or the use of additional resources is entirely voluntary.
Gene
Genetic Test Result
Study or Resource
Description
Provides information about many clinical research studies from around the world. For more information visit: https://clinicaltrials.gov
This study is being done to evaluate the frequency and clinical phenotype of BAP1 hereditary predisposition syndrome. For more information visit: Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome – NCI.
ICARE maintains a registry of individuals who may be interested in participating in cancer research studies and provides clinical and research updates, as well as other resources. Link for patients to enroll into ICARE: https://redcap.link/ICAREconsent. Link for providers to refer patients to ICARE: https://redcap.link/ICAREreferral
The IGNITE_TX study focuses on helping families share hereditary cancer information with relatives and making decisions about genetic testing. For more information visit: https://ignitetxstudy.com
The LiFT UP study focuses on how to better estimate cancer risks for individuals with Li-Fraumeni syndrome and improve cancer and treatment strategies. For more information visit: https://liftupstudy.org
The PALB2 Interest Group studies individuals and families with disease-associated PALB2 variants. For more information visit: https://www.palb2.org/
The PROMPT registry collects data from individuals with hereditary cancer-associated variants who are willing to have their health status monitored over time. For more information visit: https://promptstudy.info
The SOROCk clinical trial compares the effects of two surgical procedures in ovarian cancer risk reduction in women with BRCA1 mutations. For more information visit: https://www.nrgoncology.org/SOROCk
Note: Information provided herein is intended for informational purposes only. Accordingly, Myriad does not endorse nor directly benefit from any study, resource information, and/or links to third-party websites included on this page.